0001127602-20-016619.txt : 20200514
0001127602-20-016619.hdr.sgml : 20200514
20200514170007
ACCESSION NUMBER: 0001127602-20-016619
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200512
FILED AS OF DATE: 20200514
DATE AS OF CHANGE: 20200514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kim Lorence H.
CENTRAL INDEX KEY: 0001643746
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 20878685
MAIL ADDRESS:
STREET 1: C/O SERES HEALTH, INC.
STREET 2: 161 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-05-12
0001682852
Moderna, Inc.
MRNA
0001643746
Kim Lorence H.
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
Chief Financial Officer
Common Stock
2020-05-12
4
M
0
11643
12.21
A
1234153
D
Common Stock
2020-05-12
4
M
0
229357
10.90
A
1463510
D
Common Stock
2020-05-12
4
S
0
35182
62.56
D
1428328
D
Common Stock
2020-05-12
4
S
0
31948
63.57
D
1396380
D
Common Stock
2020-05-12
4
S
0
104544
64.67
D
1291836
D
Common Stock
2020-05-12
4
S
0
61412
65.47
D
1230424
D
Common Stock
2020-05-12
4
S
0
5677
66.43
D
1224747
D
Common Stock
2020-05-12
4
S
0
2237
67.32
D
1222510
D
Stock Option (Right to Buy)
10.90
2020-05-12
4
M
0
229357
0
D
2026-02-23
Common Stock
229357
0
D
Stock Option (Right to Buy)
12.21
2020-05-12
4
M
0
11643
0
D
2027-02-23
Common Stock
11643
286522
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.04 to $63.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.07 to $64.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.09 to $65.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.10 to $66.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.12 to $66.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.16 to $67.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
This option is fully vested and exercisable.
25% of this option vested and became exercisable on February 22, 2018, with the remainder vesting in 12 equal quarterly installments thereafter.
/s/ Lori Henderson, as Attorney-in-Fact
2020-05-14